8-K: enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

enGene Holdings Inc. announced its financial results for the second quarter ended April 30, 2025, and provided a business update, highlighting progress with the LEGEND study and BLA filing plans.

Summary

• enGene reported financial results for the second quarter ended April 30, 2025.
• The company is progressing with the LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, with additional preliminary data anticipated in the second half of 2025.
• The Biologics License Application (BLA) filing is planned for mid-2026 and remains on track.
• EMA Scientific Advice was completed, indicating data could be suitable for a Contingent Marketing Authorization Application.
• Cash and marketable securities totaled $251.5 million as of April 30, 2025, expected to provide runway into 2027.
• Total operating expenses for the three months ended April 30, 2025, were $27.1 million, compared to $17.3 million for the same period in 2024.
• Net loss attributable to common shareholders was approximately $25.8 million, or $0.51 per share, compared to approximately $15.0 million, or $0.38 per share, for the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in the LEGEND study, the EMA feedback, and the cash runway. However, the increased net loss tempers the overall sentiment.

Positives

• LEGEND study enrollment is strong, positioning the company to stay on track for trial updates in the second half of 2025 and a potential BLA filing in mid-2026.
• EMA indicated that detalimogene data could be suitable for a Conditional Marketing Authorization Application (CMA) submission.
• Cash and marketable securities of $251.5 million are expected to fund operations into 2027.
• Amy Pott was appointed as Chief Global Commercialization Officer to lead commercialization planning and execution.
• The company expanded its clinical footprint for the LEGEND study with the addition of trial sites in Europe and Asia.
• BIOTECanada Gold Leaf Biotech Company of the Year Award Winner.

Negatives

• Net loss attributable to common shareholders increased to $25.8 million, or $0.51 per share, for the three months ended April 30, 2025, compared to $15.0 million, or $0.38 per share, for the same period in 2024.
• Total operating expenses increased to $27.1 million for the three months ended April 30, 2025, compared to $17.3 million for the same period in 2024.

Risks

• The company's ability to recruit and retain qualified scientific and management personnel.
• The company's ability to establish clinical trial sites and enroll patients in its clinical trials.
• The company's ability to execute on the company's clinical development plans and ability to secure regulatory approval on anticipated timelines.
• Other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission (SEC) on EDGAR, including those described in the Risk Factors section of the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2024.

Future Outlook

The company expects to provide an update from LEGEND's pivotal cohort in the second half of 2025 and plans for a BLA filing in mid-2026. Existing cash is expected to fund operations into 2027.

Management Comments

• Ron Cooper, Chief Executive Officer of enGene: We have seen strong enrollment in the pivotal cohort of our LEGEND study. This positions us to stay on track for our planned trial updates across all cohorts in the second half of 2025 and a potential BLA filing in mid-2026, advancing our goal to introduce a novel, non-viral therapy that could redefine treatment for patients with high-risk non-muscle invasive bladder cancer.

Industry Context

enGene is focused on developing non-viral genetic medicines for diseases with high clinical needs, specifically targeting NMIBC. The company's approach aims to overcome the limitations of viral-based gene therapies.

Comparison to Industry Standards

• Astellas Pharma is a comparable company as Amy Pott, the new Chief Global Commercialization Officer, previously served as Senior Vice President, Strategic Brand Marketing, Ophthalmics and Rare Diseases, and previously as Head of Commercial, Gene Therapies at Astellas Pharma.
• The LEGEND trial is a Phase 2 study, which is a standard stage for evaluating the safety and efficacy of a new treatment before seeking regulatory approval.
• The company is pursuing a Conditional Marketing Authorization Application (CMA) with the EMA, which is a regulatory pathway designed to expedite the availability of medicines that address unmet medical needs.

Management Changes

Stakeholder Impact

• Shareholders: The progress in the LEGEND study and the cash runway are positive for shareholders.
• Patients: Detalimogene has the potential to redefine treatment for patients with high-risk non-muscle invasive bladder cancer.
• Employees: The company is expanding its clinical footprint and hiring new executives, which is positive for employees.

Next Steps

• Provide an update from LEGEND's pivotal cohort in the second half of 2025.
• Prepare for a potential BLA filing in mid-2026.
• Continue enrollment in the LEGEND trial.
• Pursue a Conditional Marketing Authorization Application (CMA) submission with the EMA.

Key Dates

Recommendation

Keywords

enGene, detalimogene, NMIBC, LEGEND study, BLA filing, EMA, Financial Results, Biotech, Genetic Medicines, Oncology